Jazz Pharmaceuticals (JAZZ) Net Income towards Common Stockholders Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Jazz Pharmaceuticals | 14.35 Bn | 12.51 Bn | 934.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20.02% |
| Dec 31, 2025 | 8.71% |
| Sep 30, 2025 | 11.06% |
| Jun 30, 2025 | -52.17% |
| Mar 31, 2025 | 10.25% |
| Dec 31, 2024 | 20.48% |
| Sep 30, 2024 | 15.82% |
| Jun 30, 2024 | -8.49% |
| Mar 31, 2024 | -16.59% |
| Dec 31, 2023 | -10.00% |
| Sep 30, 2023 | -0.42% |
| Jun 30, 2023 | 2.69% |
| Mar 31, 2023 | 8.74% |
| Dec 31, 2022 | -24.84% |
| Sep 30, 2022 | -17.80% |
| Jun 30, 2022 | -18.90% |
| Mar 31, 2022 | -41.72% |
| Dec 31, 2021 | -17.88% |
| Sep 30, 2021 | -20.60% |
| Jun 30, 2021 | -38.98% |
| Mar 31, 2021 | 9.19% |
| Dec 31, 2020 | 10.12% |
| Sep 30, 2020 | 11.10% |
| Jun 30, 2020 | 5.77% |
| Mar 31, 2020 | -33.46% |
| Dec 31, 2019 | -1.60% |
| Sep 30, 2019 | 32.01% |
| Jun 30, 2019 | 43.23% |
| Mar 31, 2019 | 23.90% |
| Dec 31, 2017 | 46.60% |
| Sep 30, 2017 | 178.41% |
| Jun 30, 2017 | 95.65% |
| Mar 31, 2017 | 104.69% |
| Jun 30, 2016 | 28.09% |
| Mar 31, 2016 | 28.28% |
| Dec 31, 2015 | 43.97% |
| Sep 30, 2015 | 46.04% |
| Jun 30, 2015 | 53.53% |